natgillin/translations-raw huggingface dataset:
Its elimination half-life in humans, at an approximate urinary pH of 6, ranges from 5 to 8 hours. 
Poluvrijeme eliminacije u ljudi pri pH vrijednosti mokraće od približno 6 u rasponu je od 5 do 8 sati.
• decreased sense of smell 
• smanjen osjet mirisa
Caution should be exercised in patients suffering from migraine who are currently being treated with ergot alkaloid vasoconstrictors (see section 4.5). 
Potreban je oprez kod primjene lijeka u bolesnika koji pate od migrene i trenutno se liječe vazokonstriktorima iz skupine ergot-alkaloida (vidjeti dio 4.5).
Drinking alcohol while taking Aerinaze is not recommended. 
Ne preporučuje se piti alkohol dok uzimate Aerinaze.
Apnoea is treated with respiratory assistance. 
Apneja se liječi asistiranom ventilacijom.
The combination of loratadine/pseudoephedrine sulphate used in acute and multiple-dose studies, exhibited a low order of toxicity. 
Kombinacija loratadina i pseudoefedrinsulfata korištena u istraživanjima akutnih i višestrukih doza pokazala je nisku toksičnost.
Desloratadine given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. 
Desloratadin primijenjen u jednoj dnevnoj dozi od 7,5 mg nije utjecao na psihomotoričke sposobnosti ispitanika u kliničkim ispitivanjima.
• pounding or irregular heart beat 
• lupanje ili nepravilno kucanje srca
It is advisable to limit treatment to about 10 days, as during chronic administration the activity of pseudoephedrine sulphate may diminish. 
Preporučeno je ograničiti liječenje na približno 10 dana jer se djelovanje pseudoefedrinsulfata može umanjiti tijekom kronične primjene.
Central nervous system effects 
Učinci na središnji živčani sustav
Desloratadine is not removed by haemodialysis and it is not known if it is eliminated by peritoneal dialysis. 
Desloratadin se ne uklanja hemodijalizom i nije poznato može li se ukloniti peritonealnom dijalizom.
In controlled clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo. 
U kontroliranim kliničkim ispitivanjima pri preporučenoj dozi od 5 mg na dan incidencija somnolencije nije bila povećana u odnosu na placebo.
Oral administration of pseudoephedrine sulphate at the recommended dose can cause other sympathomimetic effects, such as increased blood pressure, tachycardia or manifestations of central nervous system excitation. 
Peroralna primjena pseudoefedrinsulfata u preporučenoj dozi može izazvati i druge simpatomimetičke učinke, poput povišenja krvnog tlaka, tahikardije ili znakova ekscitacije središnjeg živčanog sustava.
Pack sizes of 2, 4, 7, 10, 14 and 20 tablets. 
Veličine pakiranja od 2, 4, 7, 10, 14 i 20 tableta.
Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children, being more susceptible to develop new seizures under desloratadine treatment. 
Desloratadin je potrebno primjenjivati s oprezom u bolesnika s napadajima u osobnoj ili obiteljskoj anamnezi, a osobito u male djece, koja su osjetljivija na razvoj novih napadaja tijekom liječenja desloratadinom.
No pre-clinical studies have been performed with Aerinaze. 
Nisu provedena neklinička ispitivanja s lijekom Aerinaze.
The combination was not more toxic than their individual components, and observed effects were generally related to the pseudoephedrine sulphate component. 
Toksičnost ove kombinacije nije bila veća od toksičnosti njezinih sastavnica, a opaženi učinci u pravilu su bili povezani s pseudoefedrinsulfatom.
Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1receptor antagonist activity. 
Desloratadin je nesedativan, dugodjelujući antagonist histamina sa selektivnim antagonističkim djelovanjem na periferne H1-receptore.
Desloratadine and pseudoephedrine sulphate have been identified in breastfed newborns/infants of treated women. 
Desloratadin i pseudoefedrinsulfat su nađeni u dojenoj novorođenčadi/dojenčadi liječenih žena.
Do not use this medicine after the expiry date which is stated on the outer carton and blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake "EXP".
• a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke. 
• anamnezu hemoragijskog moždanog udara ili imaju čimbenike rizika koji bi mogli povećati rizik od hemoragijskog moždanog udara.
The rate of excretion is accelerated and the duration of action decreased in acidic urine (pH5). 
Izlučivanje je brže, a trajanje djelovanja kraće u uvjetima kisele mokraće (pH 5).
In a single dose pharmacokinetic study with Aerinaze, plasma concentration of desloratadine can be detected within 30 minutes of administration. 
U farmakokinetičkom ispitivanju primjene jedne doze lijeka Aerinaze koncentracija desloratadina u plazmi može se otkriti u roku od 30 minuta nakon primjene.
In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. 
U nizu farmakokinetičkih i kliničkih ispitivanja 6% ispitanika imalo je višu koncentraciju desloratadina u plazmi.
Concurrent administration with other sympathomimetics (decongestants, anorexogenics or amphetamine-type psychostimulants, antihypertensive medicinal products, tricyclic antidepressants and other antihistamines) may result in critical hypertension reactions (see section 4.4). 
Istodobna primjena s drugim simpatomimeticima (dekongestivima, anorekticima ili psihostimulansima amfetaminske skupine, antihipertenzivima, tricikličkim antidepresivima i drugim antihistaminicima) može dovesti do kritičnih hipertenzivnih reakcija (vidjeti dio 4.4).
After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system. 
Nakon peroralne primjene desloratadin selektivno blokira periferne histaminske H1-receptore jer ne prodire u središnji živčani sustav.
At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. 
Ne očekuje se da bi u preporučenoj dozi ovaj lijek mogao utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Do not take more tablets than recommended on the label. 
Nemojte uzeti više tableta nego što je preporučio liječnik.
As much as possible of the amount administered should be removed before the next instillation. 
Prije sljedećeg ispiranja treba odstraniti što veću količinu primijenjene tekućine.
Pharmacotherapeutic group: Nasal preparations, nasal decongestants for systemic use, ATC code: R01BA52. 
Farmakoterapijska skupina: Pripravci za liječenje bolesti nosa, nazalni dekongestivi za sustavnu primjenu, ATK oznaka: R01BA52.
2 modified-release tablets 4 modified-release tablets 7 modified-release tablets 10 modified-release tablets 14 modified-release tablets 20 modified-release tablets 
2 tablete s prilagođenim oslobađanjem 4 tablete s prilagođenim oslobađanjem 7 tableta s prilagođenim oslobađanjem 10 tableta s prilagođenim oslobađanjem 14 tableta s prilagođenim oslobađanjem 20 tableta s prilagođenim oslobađanjem
Aerinaze is indicated in adults and adolescents 12 years and older for the symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion. 
Aerinaze je indiciran u odraslih i adolescenata u dobi od 12 ili više godina za liječenje simptoma sezonskog alergijskog rinitisa kada je praćen kongestijom nosa.
Fertility There are no data available on male and female fertility. 
Plodnost Nema dostupnih podataka o plodnosti u muškaraca i žena.
The safety and efficacy of Aerinaze have not been established in patients with impaired renal or hepatic function, and there are insufficient data to give adequate dose recommendations. 
Nisu ustanovljene sigurnost i djelotvornost lijeka Aerinaze u bolesnika s oštećenom funkcijom bubrega ili jetre i nema dovoljno podataka da bi se mogle dati odgovarajuće preporuke za doziranje.
• Patients receiving digitalis (see section 4.5) 
• u bolesnika koji uzimaju digitalis (vidjeti dio 4.5).
Reversible and irreversible MAO inhibitor(s) may cause: risk of vasoconstriction and increased blood pressure. 
Reverzibilni i ireverzibilni MAO-inhibitor(i) mogu izazvati: rizik od vazokonstrikcije i povišenog krvnog tlaka.
• increased body movement 
• pojačani pokreti tijela
Adverse reactions seen with Aerinaze 
Nuspojave opažene uz Aerinaze
One of the active ingredients in Aerinaze, pseudoephedrine sulphate, has the potential to be abused and large doses of pseudoephedrine sulphate can be toxic. 
Jedna od djelatnih tvari u lijeku Aerinaze, pseudoefedrinsulfat, se može zlorabiti, a velike doze pseudoefedrinsulfata mogu biti otrovne.
In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying. 
U ispitivanju učinka jedne doze u odraslih, desloratadin u dozi od 5 mg nije utjecao na standardna mjerila uspješnosti upravljanja letjelicom, uključujući pojačan subjektivni osjećaj pospanosti i zadatke vezane uz pilotiranje.
Caution should also be exercised in patients being treated with other sympathomimetics (see section 4.5). 
Oprez je potreban i u bolesnika koji se liječe drugim simpatomimeticima (vidjeti dio 4.5), uključujući:
Food had no effect on the bioavailability (Cmax and AUC) of desloratadine or pseudoephedrine sulphate. 
Hrana nije utjecala na bioraspoloživost (Cmax i AUC) desloratadina ni pseudoefedrinsulfata.
The blister consists of clear polychlorotrifluorethylene/polyvinyl chloride (PCTFE/PVC) film, sealed with a vinyl heat seal coated aluminium foil. 
Blister se sastoji od prozirnog poliklorotrifluoroetilenskog (PCTFE)/polivinilkloridnog (PVC) filma prekrivenog aluminijskom folijom presvučenom toplinski zalijepljenim vinilom.
In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. 
U farmakokinetičkom ispitivanju višestrukih doza provedenom s tabletama desloratadina u zdravih odraslih ispitanika, pronađena su četiri ispitanika sa sporim metaboliziranjem desloratadina.
Adsorption of active substance remaining in the stomach may be attempted by administration of active charcoal suspended in water. 
Može se pokušati adsorpcija preostale djelatne tvari u želucu primjenom vodene suspenzije aktivnog ugljena.
The administration of Aerinaze should be discontinued at least 48 hours before skin tests since antihistamines maybe prevent or reduce otherwise positive reaction to dermal reactivity index. 
Primjenu lijeka Aerinaze treba prekinuti najmanje 48 sati prije provođenja kožnih alergijskih testova jer antihistaminici mogu spriječiti ili umanjiti stupanj pozitivne kožne reakcije.
When Aerinaze should be used 
Kada se koristi Aerinaze
However, in a clinical pharmacology trial desloratadine taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol. 
Međutim, u kliničkom farmakološkom ispitivanju desloratadin primijenjen istodobno s alkoholom nije pojačao štetne učinke alkohola na psihomotoričke sposobnosti.
Pharmacodynamic effects The pharmacodynamic effects of Aerinaze tablets are directly related to that of its components. 
Farmakodinamički učinci lijeka Aerinaze su izravno povezani s farmakodinamikom njegovih sastavnica.
Aerinaze tablets contain a combination of two active ingredients, desloratadine which is an antihistamine and pseudoephedrine sulphate which is a decongestant. 
Aerinaze tablete sadrže kombinaciju dviju djelatnih tvari - desloratadina, koji je antihistaminik i pseudoefedrinsulfata, koji je dekongestiv.
Common: the following may affect up to 1 in 10 people 
Često: mogu se javiti u do 1 na 10 osoba
Aerinaze tablets are packed as 2, 4, 7, 10, 14, or 20 tablets in blisters comprised of laminate blister film and foil lidding. 
Aerinaze tablete dostupne su u pakiranjima od 2, 4, 7, 10, 14 ili 20 tableta u perforiranim blisterima, napravljenima od laminiranog blister filma prekrivenog folijom.
• abnormal liver function tests 
• odstupanja od normalnih vrijednosti testova jetrene funkcije
These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours. 
U tih je ispitanika Cmax desloratadina bila oko 3 puta viša od uobičajene približno 7 sati nakon uzimanja lijeka, a poluvijek u terminalnoj fazi iznosio je približno 89 sati.
• dry throat 
• suho grlo
Aerinaze is supplied in blisters comprised of laminate blister film and foil lidding. 
Aerinaze je dostupan u blisterima, napravljenima od laminiranog blister filma prekrivenog folijom.
Fertility There is no data available on male/female fertility. 
Plodnost Nema dostupnih podataka o plodnosti u muškaraca/žena.
Decongestants help to clear nasal congestion (blocked/stuffy nose). 
Dekongestivi pomažu smanjiti kongestiju nosa (začepljen/pun nos).
After improvement of the congestive condition of the mucosae of the upper airway, treatment may be maintained with desloratadine alone, if necessary. 
Nakon ublažavanja kongestije sluznice gornjih dišnih puteva liječenje se, po potrebi, može nastaviti samo desloratadinom.
Hypertension can be controlled with an adrenoceptor-blocking agent and tachycardia with a beta-blocking agent. 
Hipertenzija se može regulirati lijekom iz skupine blokatora adrenergičkih receptora, a tahikardija beta-blokatorom.
No interaction studies have been performed with the combination of desloratadine and pseudoephedrine sulphate. 
Nisu provedena ispitivanja interakcija s kombinacijom desloratadina i pseudoefedrinsulfata.
Patients of 60 years or older are more likely to experience adverse reactions to sympathomimetic medicinal products, such as pseudoephedrine sulphate. 
Bolesnici u dobi od 60 ili više godina skloniji su razvoju nuspojava na simpatomimetike poput pseudoefedrinsulfata.
Aerinaze is not recommended for use in children below the age of 12 years. 
Ne preporučuje se primjena lijeka Aerinaze u djece mlađe od 12 godina.
No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol. 
Nisu ustanovljene značajne razlike u rezultatima psihomotoričkih testova između skupine koja je primala desloratadin i one koja je dobivala placebo, bez obzira jesu li uz lijek uzimali i alkohol.
There is insufficient information on the effects of desloratadine and pseudoephedrine sulphate in newborns/infants. 
Nema dovoljno podataka o učinku desloratadina i pseudoefedrinsulfata na novorođenčad/dojenčad.
Pseudoephedrine sulphate Antacids increase the rate of pseudoephedrine sulphate absorption, kaolin decreases it. 
Pseudoefedrinsulfat Antacidi povećavaju brzinu apsorpcije pseudoefedrinsulfata, dok je kaolin smanjuje.
How to take Aerinaze 
Kako uzimati Aerinaze
Pseudoephedrine sulphate (d-isoephedrine sulphate) is a sympathomimetic agent with mostly mimetic activity in comparison with the -activity. 
Pseudoefedrinsulfat (d-izoefedrinsulfat) je simpatomimetik koji ima pretežno α-mimetičko djelovanje za razliku od β-mimetičkog djelovanja.
Aerinaze tablets relieve symptoms associated with seasonal allergic rhinitis (hay fever), such as, sneezing, runny or itchy nose, and eyes, when accompanied by nasal congestion in adults and adolescents 12 years of age and older. 
Aerinaze tablete ublažavaju simptome povezane sa sezonskim alergijskim rinitisom (peludnom groznicom), poput kihanja, curenja ili svrbeži nosa te suzenja ili svrbeži očiju, kada je uz njih prisutna i kongestija nosa u odraslih osoba i adolescenata u dobi od 12 ili više godina.
Cardiovascular and general effects 
Kardiovaskularni i opći učinci
Sympathomimetic medicines reduce the antihypertensive effect of α-methyldopa, mecamylamine, reserpine, veratrum alkaloids, and guanethidine. 
Simpatomimetici umanjuju antihipertenzivno djelovanje α-metildope, mekamilamina, rezerpina, alkaloida čemerike i gvanetidina.
Dihydroergotamine, ergotamine, methylergometrine: risk of vasoconstriction and increase in blood pressure. 
Dihidroergotamin, ergotamin i metilergometrin: postoji rizik od vazokonstrikcije i povišenja krvnog tlaka.
The following side effects have been seen in studies: 
Sljedeće su nuspojave zabilježene u kliničkim ispitivanjima:
• sugar in urine 
• šećer u mokraći
Certain conditions may make you unusually sensitive to the decongestant pseudoephedrine sulphate contained in this medicine. 
Neka stanja mogu pojačati osjetljivost na dekongestiv pseudoefedrinsulfat, koji je sastojak ovog lijeka.
Other symptoms may include: headache, anxiety, micturition difficulty, muscle weakness and tenseness, euphoria, excitement, respiratory failure, cardiac arrhythmias, tachycardia, palpitations, thirst, perspiration, nausea, vomiting, precordial pain, dizziness, tinnitus, ataxia, blurred vision and hypertension or hypotension. 
Ostali simptomi mogu obuhvaćati: glavobolju, anksioznost, otežano mokrenje, slabost i napetost mišića, euforiju, uzbuđenje, zatajenje disanja, srčane aritmije, tahikardiju, palpitacije, žeđ, znojenje, mučninu, povraćanje, prekordijalnu bol, omaglicu, tinitus, ataksiju, zamagljen vid te hipertenziju ili hipotenziju.
- Pseudoephedrine sulphate 
• Pseudoefedrinsulfat
Distribution Pseudoephedrine sulphate is presumed to cross the placenta and the haematoencephalic barrier. 
Pretpostavlja se da pseudoefedrinsulfat prolazi kroz placentu i krvno-moždanu barijeru.
What Aerinaze contains - The active substances are desloratadine and pseudoephedrine sulphate. 
Što Aerinaze sadrži - Djelatne tvari su desloratadin i pseudoefedrinsulfat.
• antihypertensive medicinal products 
• antihipertenzive
Aerinaze is not recommended for use in patients with impaired renal or hepatic function. 
Ne preporučuje se primjena lijeka Aerinaze u bolesnika s oštećenjem funkcije bubrega ili jetre.
• bromocriptine 
• bromokriptinom
• aggression 
• agresija
• Patients with hypertension 
• u bolesnika s hipertenzijom
A component interaction study demonstrated that the exposure (Cmax and AUC) of pseudoephedrine sulphate following administration of pseudoephedrine sulphate alone was bioequivalent to pseudoephedrine sulphate exposure following administration of the Aerinaze tablet. 
Ispitivanje interakcija sastavnica lijeka pokazalo je da je izloženost pseudoefedrinsulfatu (Cmax i AUC) nakon primjene samog pseudoefedrinsulfata bioekvivalentna izloženosti pseudoefedrinsulfatu nakon primjene Aerinaze tableta.
• urinary retention, 
• retenciju mokraće,
How Aerinaze works 
Kako djeluje Aerinaze
In addition, the decongestant efficacy of Aerinaze tablets, as measured by nasal stuffiness/congestion, was significantly greater than desloratadine alone over the 2-week treatment period. 
Nadalje, dekongestivna djelotvornost tableta Aerinaze tijekom 2 tjedna liječenja, mjerena na osnovi začepljenosti/kongestije nosa, bila je značajno veća nego učinak samog desloratadina.
Aerinaze is a blue and white oval bilayer modified-release tablet with “D12” debossed in the blue layer. 
Aerinaze je plavo-bijela ovalna dvoslojna tableta s prilagođenim oslobađanjem, s utisnutom oznakom "D12" na plavom sloju.
Blue and white bilayer oval tablet with “D12” branded to blue layer. 
Plavo-bijela, dvoslojna ovalna tableta, s oznakom "D12" na plavom sloju.
Short acting barbiturates, diazepam or paraldehyde may be administered to control seizures. 
Za kontrolu konvulzija mogu se primijeniti kratkodjelujući barbiturati, diazepam ili paraldehid.
• lisuride, pergolide: risk of vasoconstriction and increase in blood pressure. 
• lizuridom i pergolidom: zbog rizika od vazokonstrikcije i povišenja krvnog tlaka.
Uncommon: the following may affect up to 1 in 100 people 
Manje često: mogu se javiti u do 1 na 100 osoba
Use in children and adolescents Do not give this medicine to children less than 12 years of age. 
Nemojte davati ovaj lijek djeci mlađoj od 12 godina.
Alcohol use should be avoided during Aerinaze treatment. 
Tijekom liječenja lijekom Aerinaze treba izbjegavati alkohol.
Sympathomimetics 
Simpatomimetici
Symptoms may vary from CNS depression (sedation, apnoea, diminished mental alertness, cyanosis, coma, cardiovascular collapse) to CNS stimulation (insomnia, hallucination, tremors, convulsions) with possible fatal outcome. 
Simptomi predoziranja većinom su simpatomimetičke prirode, a mogu varirati od depresije SŽS-a (sedacija, apneja, smanjena mentalna budnost, cijanoza, koma, kardiovaskularni kolaps) do stimulacije SŽS-a (nesanica, halucinacije, tremor, konvulzije) s mogućim smrtnim ishodom.
Do not take Aerinaze: - if you are allergic to desloratadine, pseudoephedrine sulphate, adrenergic medicines, or any of the other ingredients of this medicine (listed in section 6) or to loratadine - if you have high blood pressure, heart or blood vessel disease or a history of stroke - if you have glaucoma, difficulty in urinating, urinary tract blockage, or an overactive thyroid - if you are taking monoamine oxidase (MAO) inhibitor (a class of antidepressant medicines) 
Nemojte uzimati Aerinaze: - ako ste alergični na desloratadin, pseudoefedrinsulfat, adrenergičke lijekove ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.), ili na loratadin - ako imate visok krvni tlak, bolest srca ili krvnih žila ili ste imali moždani udar - ako imate glaukom, poteškoće s mokrenjem, blokadu mokraćnih puteva ili prekomjeran rad štitnjače - ako uzimate inhibitore monoamino-oksidaze (MAO-inhibitore, vrstu lijekova za liječenje depresije) ili ste ih prestali uzimati u proteklih 14 dana.
In both trials, the antihistaminic efficacy of Aerinaze tablets as measured by total symptom score, excluding nasal congestion, was significantly greater than pseudoephedrine sulphate alone over the 2-week treatment period. 
U oba je ispitivanja antihistaminska djelotvornost tableta Aerinaze tijekom 2 tjedna liječenja, mjerena na osnovi ukupnih simptoma bez kongestije nosa, bila značajno veća nego učinak samog pseudoefedrinsulfata.
Other adverse reactions reported for desloratadine during the post-marketing period are listed hereunder. 
U nastavku su navedene ostale nuspojave prijavljene za desloratadin nakon stavljanja lijeka u promet.
Other vasoconstrictors used as nasal decongestant, by oral or nasal route (phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline…): risk of vasoconstriction. 
Drugi vazokonstriktori koji se koriste kao nazalni dekongestivi, bilo peroralnim ili nazalnim putem (fenilpropanolamin, fenilefrin, efedrin, oksimetazolin, nafazolin…): postoji rizik od vazokonstrikcije.
- The other ingredients are: Ingredients in the blue, immediate-release layer: maize starch, microcrystalline cellulose, edetate disodium, citric acid, stearic acid and colorant (Indigo Carmine E132, Aluminum lake). 
- Drugi sastojci su: Sastojci u plavom sloju s trenutnim oslobađanjem: kukuruzni škrob, mikrokristalična celuloza, dinatrijev edetat, citratna kiselina, stearatna kiselina i bojilo (indigo carmine aluminium lake (E132)).
White, sustained-release layer hypromellose 2208 microcrystalline cellulose povidone K30 silicon dioxide magnesium stearate. 
Bijeli sloj s produljenim oslobađanjem hipromeloza 2208 celuloza, mikrokristalična povidon K30 silicijev dioksid magnezijev stearat.
The interaction with Aerinaze and alcohol has not been studied. 
Nije ispitivana interakcija lijeka Aerinaze s alkoholom.
• Patients with cardiac arrhythmias 
• u bolesnika sa srčanim aritmijama
Ingredients in the white, sustained-release layer: hypromellose 2208, microcrystalline cellulose, povidone K30, silicon dioxide and magnesium stearate. 
Sastojci u bijelom sloju s produljenim oslobađanjem: hipromeloza 2208, mikrokristalična celuloza, povidon K30, silicijev dioksid i magnezijev stearat.
Adverse reactions considered by investigators to be causally related to Aerinaze are listed below by System Organ Class. 
Nuspojave za koje su ispitivači smatrali da su uzročno povezane s primjenom lijeka Aerinaze navedene su prema organskim sustavima.